Sp985
WILL MORE ACID SUPPRESSION BE THE ANSWER
Date
May 8, 2023
Explore related products in the following collection:
Tracks
Related Products
AGA Donald O. Castell, MD, Lecture — The Diagnosis and Treatment of Esophageal Motility Disorders: Where Do We Stand?
This session provides a deeper understanding of how and when to use our current state of the art tools for physiology testing. Audience members will appreciate the nuances of esophageal motility reading, when to order which pH test for reflux symptoms…
WHAT TO DO ABOUT EGJOO?
This session provides a deeper understanding of how and when to use our current state of the art tools for physiology testing. Audience members will appreciate the nuances of esophageal motility reading, when to order which pH test for reflux symptoms…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
AGA Best Practices in Eosinophilic Esophagitis
The field of EoE is undergone remarkable and dramatic changes in the last decade. With the advent of biologics, a better understanding of all current treatment options and how to pick the right option for a given patient is needed…